LB067 - FASTING FOLLOWED BY TIME-RESTRICTED EATING LEADS TO SUSTAINED SYMPTOM IMPROVEMENT IN PATIENTS WITH PARKINSON’S DISEASE

LB067

FASTING FOLLOWED BY TIME-RESTRICTED EATING LEADS TO SUSTAINED SYMPTOM IMPROVEMENT IN PATIENTS WITH PARKINSON’S DISEASE

B. Hansen^1,*, K. Roomp¹, R. Villette¹, B. Mollenhauer², S. Schade², P. Wilmes¹, J. Schneider¹

¹Luxembourg Centre for systems Biomedicine, University of Luxembourg, Esch, Belval, Luxembourg, ²Movement disorders and Parkinson’s Disease, Paracelsus-Kliniken, Kassel, Germany

Rationale: Fasting, including prolonged fasting (PF) and time-restricted eating (TRE), has emerged as a compelling dietary regimen garnering attention for its potential health benefits. It has been suggested that these benefits may be mediated by effects on metabolic and inflammatory pathways. Furthermore, TRE has been demonstrated to influence the composition of the gut microbiome, which plays a critical role in neuroinflammation and has been implicated in the pathogenesis of Parkinson’s disease (PD).

Methods: Here, we assessed the effects of one week of PF followed by 12 months of TRE in patients diagnosed with PD by analyzing specific PD questionnaires, such as the Movement Disorder Society‐Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) and the Non-Motor Symptoms Scale (NMSS). Additionally, dietary information was recorded and analyzed, to discern any inadvertent dietary alterations that may have occurred.

Results: PD symptoms showed a significant improvement, with a 34% reduction in MDS-UPDRS Part 3 (the clinician-administered motor examination) and a 36% reduction in NMSS (P-value < 0.01). These improvements were sustained throughout the study and accompanied by decreases in BMI and heart rate. Additionally, significant shifts in the dietary pattern of the patients with PD were observed, leaning towards a decreased consumption of animal products and a higher consistency in the meal timing.

Conclusion: Fasting combined with a maintenance diet offers a promising treatment strategy for patients with PD.

Disclosure of Interest: None declared